Literature DB >> 9301548

Detection of p53 in inflammatory tissue and lymphocytes using immunohistology and flow cytometry: a critical comment.

A Nickels1, H Selter, M Pfreundschuh, M Montenarh, B Koch.   

Abstract

AIMS: To analyse the expression of p53 in lymphatic cells found in inflammatory tissues and the peripheral blood by immunological methods.
METHODS: Immunohistological analysis of synovial tissues from patients with rheumatoid arthritis and flow cytometric analysis of peripheral blood lymphocytes were performed with anti-p53 antibodies from different sources.
RESULTS: The anti-p53 antibodies PAb240, PAb421, and PAb1801 from one supplier bound to the cytoplasm of lymphocytes, fibroblasts, and endothelial cells in rheumatoid synovial tissue, while the same anti-p53 antibodies from other sources and the p53 specific antibodies PAb1620 and DO1 were negative. Using flow cytometry, the antibodies that labelled cells in inflammatory tissues were shown to bind also to peripheral lymphocytes, while the antibodies that were negative in immunohistology did not react with peripheral blood lymphocytes. p53 expression could be confirmed by western blot in rheumatoid synovial tissue, but not in peripheral blood lymphocytes using PAb421 and PAb240 antibodies from our own laboratory, which had been negative in immunohistology.
CONCLUSIONS: Demonstration of p53 by western blot is more sensitive and reliable than immunohistology and flow cytometry. Western blot is the gold standard for the demonstration of p53 expression and should be used, whenever possible, to confirm p53 expression in normal tissue shown by immunohistology or flow cytometry. All other reports on p53 expression, especially those obtained using antibodies with an unusual staining pattern must be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9301548      PMCID: PMC500108          DOI: 10.1136/jcp.50.8.654

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  45 in total

1.  Morphometric analysis of blood vessels in synovial membranes obtained from clinically affected and unaffected knee joints of patients with rheumatoid arthritis.

Authors:  O FitzGerald; M Soden; G Yanni; R Robinson; B Bresnihan
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

2.  A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40.

Authors:  J Milner; A Cook; M Sheldon
Journal:  Oncogene       Date:  1987       Impact factor: 9.867

3.  Monoclonal antibodies specific for simian virus 40 tumor antigens.

Authors:  E Harlow; L V Crawford; D C Pim; N M Williamson
Journal:  J Virol       Date:  1981-09       Impact factor: 5.103

4.  Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro.

Authors:  J Bártek; J Bártková; B Vojtĕsek; Z Stasková; A Rejthar; J Kovarík; D P Lane
Journal:  Int J Cancer       Date:  1990-11-15       Impact factor: 7.396

Review 5.  Biochemical, immunological, and functional aspects of the growth-suppressor/oncoprotein p53.

Authors:  M Montenarh
Journal:  Crit Rev Oncog       Date:  1992

6.  A PAb240+ conformation of wild type p53 binds DNA.

Authors:  K G McLure; P W Lee
Journal:  Oncogene       Date:  1996-09-19       Impact factor: 9.867

7.  The difference in p53 antioncogene transcription in human monocytes and lymphocytes.

Authors:  O A Osipovich; N I Misuno; T S Kolesnikova; A B Sudarikov; N N Voitenok
Journal:  Oncogene       Date:  1992-03       Impact factor: 9.867

8.  Abnormal expression of wild type p53 protein in normal cells of a cancer family patient.

Authors:  D M Barnes; A M Hanby; C E Gillett; S Mohammed; S Hodgson; L G Bobrow; I M Leigh; T Purkis; C MacGeoch; N K Spurr
Journal:  Lancet       Date:  1992-08-01       Impact factor: 79.321

9.  An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.

Authors:  B Vojtĕsek; J Bártek; C A Midgley; D P Lane
Journal:  J Immunol Methods       Date:  1992-07-06       Impact factor: 2.303

10.  The tissue architecture of synovial membranes in inflammatory and non-inflammatory joint diseases. I. The localization of the major synovial cell populations as detected by monoclonal reagents directed towards Ia and monocyte-macrophage antigens.

Authors:  G R Burmester; P Locher; B Koch; R J Winchester; A Dimitriu-Bona; J R Kalden; W Mohr
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

View more
  5 in total

1.  The p53 status in juvenile chronic arthritis and rheumatoid arthritis.

Authors:  H Taubert; B Thamm; A Meye; F Bartel; A K Rost; D Heidenreich; V John; J Brandt; M Bache; P Würl; H Schmidt; D Riemann
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  [Prognostic significance of immunohistochemical studies].

Authors:  M Montenarh
Journal:  HNO       Date:  2003-10       Impact factor: 1.284

3.  Over-expression of TATA binding protein (TBP) and p53 and autoantibodies to these antigens are features of systemic sclerosis, systemic lupus erythematosus and overlap syndromes.

Authors:  R Chauhan; R Handa; T P Das; U Pati
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

4.  Discrepancy between mRNA and protein expression of tumour suppressor maspin in synovial tissue may contribute to synovial hyperplasia in rheumatoid arthritis.

Authors:  J Schedel; O Distler; M Woenckhaus; R E Gay; B Simmen; B A Michel; U Müller-Ladner; S Gay
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

5.  Apoptosis and p53 expression in rat adjuvant arthritis.

Authors:  P P Tak; M S Klapwijk; S F Broersen; D A van de Geest ; M Overbeek; G S Firestein
Journal:  Arthritis Res       Date:  2000-03-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.